|
|
14200 Shady Grove Road
Rockville, MD 20850 USA
phone:(301) 309-8504
fax:(301) 309-8512
|
|
| Symbol |
HGSI |
| Exchange |
Nasdaq |
| Founded |
1993 |
| Employees |
880 |
|
|
| www.hgsi.com
|
|
| Research Sector |
Biotech Specialty Pharma |
|
 |
| Summary Description |
| Gene-Based Drugs to Treat and Cure Diseases |
|
| Management |
| H. Thomas Watkins, President and Chief Executive Officer; James H. Davis, Ph.D., J.D., Executive Vice President, General Counsel and Secretary; Barry A. Labinger, Executive Vice President and Chief Commercial Officer; David C. Stump, M.D., Executive Vice President, Research and Development; Timothy Barabe, Senior Vice President and Chief Financial Officer |
| |
|
|
|
|
|
|
|
| Keywords |
| belimumab, albinterferon, chronic hepatitis, systemic lupus, raxibacumab |
|
|
|
| Description |
|
Human Genome Sciences (HGS) is engaged in the research and development of gene-based drugs to treat and cure disease. The Company is conducting clinical trials of eight of its drugs for the treatment of diseases such as cancer, lupus, hepatitis C. |
|
| Products / Services |
HGS now has three promising products in late-stage development, moving toward commercialization: Albuferon, for patients with chronic Hepatitis C; BENLYSTA (formerly LymphoStat-B) for patients with lupus; and ABthrax, designed to address the threat of inhalation anthrax. The company's emerging, high-potential mid-stage pipeline is led by its TRAIL receptor antibodies for cancer. HSG also has substantial financial rights to a number of products in the GlaxoSmithKline clinical pipeline, including darapladib for treatment of chronic coronary heart disease and Syncria (albiglutide) for patients with type 2 diabetes mellitus.
|
|
| Market / Customers |
The company's products address unmet needs in several high-value markets, including coronary heart disease and diabetes.
|
|
| Status |
| HSG has reported the positive results of two Phase 3 trials of Albuferon and plans to file global marketing applications in fall 2009. Two Phase 3 trials are ongoing for BENLYSTA, with results expected in July and November 2009. The company is currently developing ABthrax under a contract with the U.S. Government. |
|
|
|
|
|
|
|
Biotech & Specialty Pharma
Healthcare Services
Medical Devices & Tech
OneMedPlace Member
AdvaMed Members
